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We have shown that costimulation blockade can protect
against acute GvHD (aGvHD) in a non-humanprimatemodel.
We therefore designed a ﬁrst-in-disease trial of in vivo
CD28:CD80/86-directed costimulation blockadewith CTLA4-
Ig (abatacept) to prevent aGvHD after unrelated-donor HSCT
for patients > 12y. In this trial, 10mg/kg abatacept was
administered IV on day -1, +5, +14, +28 in addition to stan-
dard prophylaxis with cyclosporine + MTX.
Patient Characteristics and Survival: 10 patients, with
a median age of 44.5 y (17-74) were enrolled and treated. 6
received 7/8-matched and 4 received 8/8-matched URD
HSCT. 8 received PBSCs and 2 received BM. All received high-
intensity conditioning. With a median follow-up of 367 days
(262-680), 7 patients are alive and in remission and 2
patients died of relapse. One patient died, in remission, of
trauma-related multi-organ failure > 1yr post-transplant.
Feasibility, Pharmacokinetics and Pharmacodynamics:
All 10 patients received all scheduled abatacept doses,
without infusion reactions. The average peak (230.9 +/- 7.4
mg/ml) and trough (45.9 +/- 2.8 mg/ml) abatacept levels, as
well as the terminal T1/2 (19.6 +/- 1.9 days) were similar to
healthy controls. Importantly, as has been established in
vitro, patients receiving abatacept demonstrated signiﬁcant
inhibition of post-transplant CD4+ T cell proliferation (with
>80% reduction of Ki-67+ proliferating CD4+ T cells at d +28
compared to controls not receiving abatacept, Figure 1A).
Figure 1A. Patients Treated with Abatacept Exhibit Fewer Proliferating CD4+
T Cells After Transplant. Black: Control patients treated with cyclosporine/
MTX alone (n¼6), Red: Patients treated with cyclosporine/MTX + Abatacept
(n ¼ 10)
Engraftment: All patients achieved neutrophil engraftment
(median d+16.5) and donor engraftment (100% CD33
chimerism at d+30). Lymphocyte recovery was rapid: Day
+100 counts showed ALC¼ 1053 +/- 259 cells/ml, total T cells
¼ 741 +/- 208 cells/ml, and CD8+ T cells¼ 381 +/- 99 cells/ml.
The Day +100 CD4+ T cells ¼ 285 +/- 105 cells/ml, not
signiﬁcantly different from historical controls (n ¼ 43) that
received CNI/MTX aGvHD prophylaxis without abatacept
(262 +/-26 cells/ml).
GvHD: Patients receiving the abatacept-containing regimen
had encouragingly low rates of early severe aGvHD: Two
patients developed aGvHD before day +100, with one of
these patients (Gr II) progressing to steroid-dependent
cGvHD of the liver and one patient (Gr III) with resolution of
aGvHD. The cumulative incidence of grade II-IV and III-IV
aGvHD by day +100 was thus 20% and 10%, respectively
(Figure 1B). Importantly, there was no Gr IV aGvHD, no
patient received salvage therapy for aGvHD, and there were
no deaths from aGvHD.Figure 1B. Cumulative Incidence of Grade II-IV aGvHD (left) and Gr III-IV
aGvHD (right) In Patients Through Day +100 on the Abatacept Trial. No Grade
IV aGvHD developed.
Conclusions: This trial demonstrates, for the ﬁrst time, the
feasibility of adding in vivoTcell costimulation blockadewith
abatacept for aGvHD prevention. The decreased CD4+ T cell
proliferation post-transplant and the encouragingly low rates
of early, severe aGvHD suggest that costimulation blockade
may be an effective agent for aGvHD prophylaxis and support
the conduct of a larger, randomized phase 2 study.440
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We have developed a systems-biology approach to studying
GvHD, using whole-transcriptome analysis of pathogenic T
cells. Using computational methods, we have identiﬁed, for
the ﬁrst time, the transcriptional networks that drive
primate GvHD, and that lead to its partial control through
mTOR inhibition with sirolimus.
Methods: CD3+/CD20- T cells were puriﬁed ﬂow cytometri-
cally from 4 cohorts: (1) Healthy Controls (HC n ¼ 15); (2)
Auto-HSCT recipients (n ¼ 3); (3) Untreated Allo-HSCT
recipients who developed severe GvHD, (GvHD n ¼ 4); and
(4) Allo-HSCT recipients receiving sirolimus alone (Sirolimus
n ¼ 4). Puriﬁcation of T cells and RNA was followed by
primate-speciﬁc Affymetrix Gene Array analysis.
Computation: Gene array signals were processed using the
Robust Multichip Averaging Method. Principal Component
Analysis (PCA) revealed that variation was primarily deter-
mined by the experimental cohort (Figure 1A). This result
was critical, and conﬁrmed that transcriptomics could be
applied to identify genes and pathways controlling GvHD.
Differentially expressed genes (DE) were deﬁned, yielding
unique and overlapping gene signatures, with 775 DE genes
between GvHD and HC and 286 DE genes between Sirolimus
and HC (Figure 1B). Finally, using Ingenuity Pathway Analysis
(IPA) we characterized gene signatures according to molec-
ular pathways (Figure 1C).
Results: T cells from animals with severe aGvHD showed
transcriptional signs of rampant proliferation and cytotox-
icity, but also of cell death. IPA identiﬁed highly statistically
signiﬁcant upregulation of Cell Cycle as well as Cell Traf-
ﬁcking and Inﬂammatory Response networks (Figure 1C, P <
.001) These networks contained some expected genes and
some surprises. Thus, GvHD was associated with upregula-
tion of JAK and IFN signaling ( P < .001), but unexpectedly,
was also associated with upregulation of the Sonic Hedgehog
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represent targetable pathways with clinically-available novel
therapeutics.
Sirolimus resulted in partial downregulation of proliferation
and cytotoxicity pathways. However, many genes and
networks were shared between the Sirolimus and GvHD
cohorts, indicating inadequately controlled activation. These
prominently included upregulation of the FOXM1 and IRF8
transcription factors, involved in cell cycle progression and
interferon signaling (P < .01), respectively. Both GvHD and
Sirolimus also demonstrated upregulation of the CD28, CCR5,
IL-12 and IL-17 pathways (P < .05), all targetable with FDA-
approved therapeutics (CTLA4-Ig, maraviroc, ustekinumab).
Conclusions: This is theﬁrst description of the primateGvHD
transcriptome. This network approach has identiﬁed previ-
ously unappreciated genes and pathways associated with
GvHD, for which several novel therapeutic strategies are
immediately available for pre-clinical and clinical evaluation.
Figure 1. The Primate GvHD Transcriptome: (A) Principal Component Analysis
(PCA) reveals that maximal variation between the arrays was determined by
the experimental cohort. (B) Differentially Expressed (DE) Genes Compared to
Healthy Controls (HC). Left: Shown Are numbers of Up- (red) and Down- (blue)
regulated genes in Auto, Sirolimus, and GvHD cohorts compared to HC. Right:
Venn Diagrams showing overlap of DE genes between the three cohorts. (C)
Ingenuity Pathway Analysis depicting gene networks differentially regulated
during GvHD. Shown are representative networks showing cell cycle (left) and
inﬂammatory response genes (right).441
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Introduction: Graft-versus-host disease (GVHD) is on of the
leading complication of allogeneic hematopoietic stem cell
transplantation (HSCT) causing signiﬁcant morbidity and
mortality. CD4+ T-cells play a critical role inmediating GVHD,
and much effort has been devoted to studying the effect of
CD4+ T-cells during the pathophysiology process of GVHD.
Even though just accounting for 5% of the total CD4+ T-cell
population, the most promising candidates are naturally
occurring CD4+CD25+ regulatory T cells (Tregs), which are on
of the regulators of immune responses. TH17 is a newly
identiﬁed T-cell lineage that secretes IL-17, a proin-
ﬂammatory cytokine. However, the functional role of TH17
cells in the development of GVHD has not been well char-
acterized in humans. The aim of our study was to charac-
terize the expression of Treg (FOXP3) and TH17-related (RORgt)
genes in peripheral blood of patients undergoing HSCT and
correlate them with the development of GVHD in HLA
identical allogeneic HSCT.
Patients and Methods: Samples were collected from
peripheral blood of 50 patients before and after HSCT and at
the time of GVHD onset. Thirty patients were diagnosed as
acute leukemia/myelodysplastic syndrome, eleven as chronic
myeloid leukemia and ten with lymphomas. Seven healthy
donors were used as controls. All patients received HLA-
identical related donor graft. Except for lymphomas patients
(n¼10), who underwent non-myeloablative conditioning,
others underwent myeloablative conditioning regimens
(n¼40). Expression of FOXP3 and RORgt were assessed by
Real-Time quantitative PCR (qPCR) using the 7500 Fast Real
Time PCR System (Applied Biosystems), by Taqman method.
Comparison among groups was performed using Graphpad
Prism 5 and Mann-Withney test.
Results: Median age for the 50 analyzed patients was 36
years-old (range: 17-60), 52% were female. 50% had GVHD,
with an average onset of 39 days after HSCT for acute GVHD
(range: 12-93) and 182 days for chronic GVHD (range: 117-
266). No signiﬁcant associationwas observed between FOXP3
expression and patients with or without GVHD. On the other
hand, RORgt showed signiﬁcantly higher expression in
patients with chronic GVHD compared to samples before
HSCT (P< .0001), without GVHD (P< .0001) and acute GVHD
(P ¼ .0006). Both FOXP3 and RORgt showed signiﬁcant
statistical decreased expression in patients compared to
healthy controls, except for RORgt expression in patients
with chronic GVHD (p¼NS).
Conclusion: RORgt showed signiﬁcantly higher expression
in patients with chronic GVHD compared to samples before
HSCT, without GVHD and acute GVHD. These ﬁndings
suggest a Th17/IL-17 mediated proinﬂammatory state
involved in chronic GVHD, showing a potential target for
GVHD control.
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